Is Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Tarsus Pharmaceuticals, Inc. at current levels.
A one-drug eye care company quietly building a billion-dollar franchise from a condition most doctors used to shrug at.
Where TARS is headed
XDEMVY is doing something unusual for a single-product launch. It is creating its own market. Demodex blepharitis affects roughly 25 million Americans, but until Tarsus showed up with a regulatory-approved treatment in late 2023, optometrists treated it with tea tree oil scrubs and a shrug. Two years in, prescriber count has crossed 20,000 and revenue has more than doubled year over year. That is the shape of a category being built from zero, not a drug fighting for share in a crowded room.
Read the full Compass Direction on TARS
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $62.26).
See the full TARS analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Tarsus Pharmaceuticals, Inc. at current levels. A one-drug eye care company quietly building a billion-dollar franchise from a condition most doctors used to shrug at.
What is TARS's Compass Score?
Tarsus Pharmaceuticals, Inc. scores 85/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for TARS?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the TARS page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.